Latest Insider Transactions at Fate Therapeutics Inc (FATE)
This section provides a real-time view of insider transactions for Fate Therapeutics Inc (FATE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of FATE THERAPEUTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of FATE THERAPEUTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 09
2022
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+46.65%
|
-
|
|
Jun 09
2022
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+44.8%
|
-
|
|
Jun 09
2022
|
Karin Jooss |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+46.76%
|
-
|
|
Jun 09
2022
|
John Mendlein |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+4.93%
|
-
|
|
Jun 09
2022
|
William H Rastetter |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+43.29%
|
-
|
|
Jun 09
2022
|
Yuan Xu |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+39.24%
|
-
|
|
Jun 09
2022
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+43.29%
|
-
|
|
Jun 09
2022
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,650
+0.07%
|
-
|
|
Jun 09
2022
|
Robert S Epstein |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+43.29%
|
-
|
|
Jun 07
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
841
-31.37%
|
$17,661
$21.89 P/Share
|
|
Jun 03
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
807
-30.1%
|
$17,754
$22.8 P/Share
|
|
Jun 03
2022
|
Timothy Coughlin |
SELL
Open market or private sale
|
Direct |
1,439
-2.44%
|
$31,658
$22.81 P/Share
|
|
Jun 03
2022
|
Robert Hershberg Director |
SELL
Open market or private sale
|
Direct |
672
-25.07%
|
$14,784
$22.75 P/Share
|
|
Jun 03
2022
|
Karin Jooss |
SELL
Open market or private sale
|
Direct |
1,483
-55.32%
|
$32,626
$22.82 P/Share
|
|
Jun 03
2022
|
John Mendlein |
SELL
Open market or private sale
|
Direct |
1,364
-0.86%
|
$30,008
$22.79 P/Share
|
|
Jun 01
2022
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
25,000
-11.67%
|
$550,000
$22.96 P/Share
|
|
Jun 01
2022
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+10.45%
|
$150,000
$6.55 P/Share
|
|
Apr 22
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.13%
|
$340,000
$34.85 P/Share
|
|
Apr 22
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.21%
|
$20,000
$2.7 P/Share
|
|
Apr 21
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.65%
|
$1,080,000
$36.23 P/Share
|
|
Apr 21
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.1%
|
$60,000
$2.7 P/Share
|
|
Apr 19
2022
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,062
-2.62%
|
$142,170
$35.37 P/Share
|
|
Apr 01
2022
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
25,000
-11.67%
|
$950,000
$38.85 P/Share
|
|
Apr 01
2022
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.53%
|
$125,000
$5.7 P/Share
|
|
Mar 14
2022
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.53%
|
$800,000
$32.37 P/Share
|
|
Mar 14
2022
|
Bahram Valamehr Chief R&D Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+10.88%
|
$50,000
$2.73 P/Share
|
|
Mar 10
2022
|
John Mendlein |
SELL
Open market or private sale
|
Direct |
31,562
-8.62%
|
$1,104,670
$35.11 P/Share
|
|
Mar 10
2022
|
John Mendlein |
BUY
Exercise of conversion of derivative security
|
Direct |
31,562
+14.18%
|
$31,562
$1.63 P/Share
|
|
Jan 25
2022
|
Cindy Tahl General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+14.97%
|
-
|
|
Jan 25
2022
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+19.0%
|
-
|
|
Jan 25
2022
|
Mark Plavsic Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+20.29%
|
-
|
|
Jan 25
2022
|
Yu Waye Chu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+17.68%
|
-
|
|
Jan 25
2022
|
Bahram Valamehr Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+15.62%
|
-
|
|
Jan 21
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.26%
|
$380,000
$38.02 P/Share
|
|
Jan 21
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.21%
|
$20,000
$2.7 P/Share
|
|
Jan 20
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-6.5%
|
$1,200,000
$40.21 P/Share
|
|
Jan 20
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.1%
|
$60,000
$2.73 P/Share
|
|
Jan 11
2022
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,965
-1.58%
|
$190,320
$48.77 P/Share
|
|
Jan 11
2022
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,770
-0.8%
|
$84,960
$48.71 P/Share
|
|
Jan 11
2022
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
4,570
-1.52%
|
$219,360
$48.78 P/Share
|
|
Jan 11
2022
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
5,419
-1.69%
|
$260,112
$48.81 P/Share
|
|
Jan 11
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
14,566
-1.64%
|
$699,168
$48.79 P/Share
|
|
Jan 10
2022
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
5,596
-1.79%
|
$257,416
$46.75 P/Share
|
|
Jan 10
2022
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
7,738
-2.3%
|
$355,948
$46.76 P/Share
|
|
Jan 10
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
34,156
-2.41%
|
$1,605,332
$47.08 P/Share
|
|
Jan 03
2022
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
50,000
-6.12%
|
$2,950,000
$59.19 P/Share
|
|
Jan 03
2022
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+18.59%
|
$300,000
$6.55 P/Share
|
|
Dec 20
2021
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,977
-12.64%
|
$958,620
$60.0 P/Share
|
|
Dec 20
2021
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,437
+10.25%
|
$505,295
$35.52 P/Share
|
|
Dec 13
2021
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.91%
|
$1,175,000
$47.61 P/Share
|